Literature DB >> 19589101

Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma.

Luca Giovanella1, Franco Keller, Luca Ceriani, Renato Tozzoli.   

Abstract

BACKGROUND: To examine the prevalence of significant interference from heterophile antibodies (HAb) in the measurement of serum thyroglobulin (Tg), we evaluated a large cohort of samples from patients with differentiated thyroid carcinoma (DTC).
METHODS: Serum Tg measurements were performed in 406 serum samples before and after incubation of each serum sample in heterophile-blocking tubes (HBT) at room temperature for 1 h. We calculated the difference between the original Tg value and the value obtained after HBT treatment. We considered any sample showing an absolute percent difference >3 SD from the mean percent difference as being affected by HAb interference.
RESULTS: We identified five patients (1%) as showing interference from HAb. Of these, three (60%) showed a false positive or falsely increased Tg concentration without any recurrence following clinical work-up; two (40%) showed a false negative or falsely reduced Tg levels, and metastases were detected in both cases by imaging procedures.
CONCLUSIONS: HAb may increase as well as reduce the measured Tg in a significant number of patients. A positive HAb interference should be suspected if Tg elevation does not fit the clinical pictures. A negative interference is a more challenging problem because increases in Tg generally occur as the first sign of recurrence of DTC. Therefore, treatment using HBT tubes of all sera referred for Tg measurement should be considered in order to prevent both unwarranted investigations or therapy, and delayed diagnosis of recurrence in patients affected by DTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589101     DOI: 10.1515/CCLM.2009.230

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  13 in total

1.  Can an undetectable value of TG and a negative neck ultrasound study be considered reliable methods to assess the completeness of thyroid ablation?

Authors:  Massimo Salvatori; Germano Perotti; Luca Giovanella; Massimo Eugenio Dottorini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-23       Impact factor: 9.236

2.  Toxoplasmic Lymphadenitis Mimicking a Metastatic Thyroid Carcinoma at (18)F-FDG-PET/CT.

Authors:  Giorgio Treglia; Massimo Bongiovanni; Luca Ceriani; Gaetano Paone; Luca Giovanella
Journal:  Nucl Med Mol Imaging       Date:  2013-09-13

Review 3.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

Review 4.  Iodine, thyroglobulin and thyroid gland.

Authors:  R Bílek; M Dvořáková; T Grimmichová; J Jiskra
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

Review 5.  Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.

Authors:  Matthew D Ringel; Fadi Nabhan
Journal:  J Clin Endocrinol Metab       Date:  2013-08       Impact factor: 5.958

6.  Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma.

Authors:  Luca Giovanella; Pierpaolo Trimboli; Frederik A Verburg; Giorgio Treglia; Arnoldo Piccardo; Luca Foppiani; Luca Ceriani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-06       Impact factor: 9.236

Review 7.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

8.  Is there a role for unstimulated thyroglobulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation?

Authors:  Hilda Wong; Kai P Wong; Thomas Yau; Vikki Tang; Roland Leung; Joanne Chiu; Brian Hung-Hin Lang
Journal:  Ann Surg Oncol       Date:  2012-05-11       Impact factor: 5.344

Review 9.  Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper.

Authors:  Luca Giovanella; Penelope M Clark; Luca Chiovato; Leonidas Duntas; Rossella Elisei; Ulla Feldt-Rasmussen; Laurence Leenhardt; Markus Luster; Camilla Schalin-Jäntti; Matthias Schott; Ettore Seregni; Herald Rimmele; Jan Smit; Frederik A Verburg
Journal:  Eur J Endocrinol       Date:  2014-04-17       Impact factor: 6.664

10.  Changes of serum midkine as a dynamic prognostic factor to monitor disease status in papillary thyroid cancer.

Authors:  Ning Li; Chunmei Zhang; Zhaowei Meng; Ke Xu; Xianghui He; Yang Yu; Qiang Jia; Xue Li; Xiangxiang Liu; Xiaoran Wang
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.